Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending September 24, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share capital movements.
- Shares Repurchased: 600,000 ordinary shares of 25 pence each.
- Repurchase Date: September 24, 2008.
- Price per Share: 1,194 pence.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,219,090,816 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 600,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data for prior periods regarding these specific metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance announcement confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules. The text explicitly states that the announcement does not constitute an offer or solicitation to purchase securities.
Investor Verification Checklist
- Verify the total number of shares in issue (5,219,090,816) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its percentage of total voting rights (9.09%).
- Note that this filing does not contain operational or financial performance data; refer to Form 20-F for comprehensive financial results.